EU approval of single dose Johnson and Johnson COVID-19 Vaccine

Approval was supported by data from the Phase III ENSEMBLE trial which demonstrated a 67% reduction in symptomatic COVID-19 disease, 85% efficacy in preventing severe disease and protection against COVID-19-related hospitalisation and death, 28 days after vaccination, vs placebo.

Source:

PharmaTimes